Consistent with former studies, HER2 mutated patients in our cohort were mainly females, never or light smokers, with poorly or moderately differentiated adenocarcinoma.10 They were younger, with more than three quarters of patients aged less than 65 years old. This evidence concerns the gene ERBB2 and adenocarcinoma.